Loading…
Novelix Pharmaceuticals (BSE 536565)₹63.24−2.20%Healthcare Research, Analytics & Technology
In the Mar 2026 quarter (standalone), Novelix Pharmaceuticals reported sales of ₹25.18 Cr, up 20.6% from Mar 2025, and net profit of ₹0.92 Cr, up 441.2% year on year. For the year to Mar 2026, sales were ₹132 Cr and net profit ₹3.01 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.96 | 0.94 | 0.51 | 0.85 | 0.61 | 3.97 | 5.31 | 20.88 | 22.34 | 36.35 | 48.42 | 25.18 |
| Expenses | 2.15 | 1.05 | 0.62 | 0.70 | 1.05 | 3.75 | 5.18 | 20.67 | 22.18 | 35.69 | 47.16 | 23.93 |
| Operating Profit | −0.18 | −0.10 | −0.10 | 0.14 | −0.43 | 0.21 | 0.12 | 0.22 | 0.17 | 0.69 | 1.30 | 1.27 |
| OPM % | −9.8% | −11.9% | −22.0% | 17.8% | −73.3% | 5.6% | 2.4% | 1.1% | 0.8% | 1.9% | 2.7% | 5.1% |
| Other Income | 0.06 | 0.06 | 0.10 | 0.14 | 0.09 | −0.09 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.00 | 0.00 | 0.00 | 0.03 | 0.02 | 0.02 | 0.04 | 0.06 |
| Profit before tax | −0.14 | −0.06 | −0.02 | 0.26 | −0.33 | 0.13 | 0.12 | 0.20 | 0.16 | 0.71 | 1.27 | 1.22 |
| Tax % | 6.7% | 0.0% | 0.0% | 0.0% | 3.0% | 0.0% | −15.3% | 14.4% | 41.2% | 26.4% | 21.9% | 26.1% |
| Net Profit | −0.18 | −0.08 | −0.04 | 0.29 | −0.36 | 0.14 | 0.16 | 0.17 | 0.12 | 0.54 | 1.01 | 0.92 |
| EPS (Rs) | −0.22 | −0.10 | −0.05 | 0.36 | −0.36 | 0.14 | 0.16 | 0.19 | 0.10 | 0.38 | 0.59 | 0.44 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.01 | 4.01 | 3.01 | 4.01 | 2.01 | 1.01 | 1.01 | 2.01 | 4.01 | 31.03 | 132 | 132 |
| Expenses | 1.01 | 3.01 | 3.01 | 3.01 | 1.01 | 4.01 | 3.01 | 2.01 | 4.01 | 31.05 | 129 | 129 |
| Operating Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −2.99 | −1.99 | 0.00 | 0.00 | 0.00 | 2.99 | 3.43 |
| OPM % | 43.0% | 5.0% | 15.0% | 6.0% | 12.0% | −244.0% | −151.0% | 0.0% | −6.0% | 0.5% | 2.6% | 2.6% |
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 |
| Profit before tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −2.99 | −1.99 | 0.00 | 0.00 | 0.00 | 2.99 | 3.36 |
| Tax % | 31.1% | 24.1% | 34.1% | −32.0% | 20.0% | 0.0% | −1.0% | 0.0% | 50.0% | 33.1% | 25.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −3.01 | −2.01 | 0.00 | 0.00 | 0.00 | 3.01 | 2.59 |
| EPS (Rs) | 0.13 | 0.20 | 0.23 | 0.32 | 0.12 | −4.06 | −1.94 | −0.08 | 0.02 | 0.09 | 1.22 | 1.51 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 7.99 | 8.00 | 8.00 | 8.00 | 8.01 | 8.00 | 7.99 | 8.00 | 8.01 | 8.01 | 10.03 | 21.07 |
| Reserves | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 4.00 | 1.00 | −1.01 | −1.01 | −1.01 | 8.02 | 25.09 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.01 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10.01 | 41.96 |
| Total Liabilities | 11.99 | 12.00 | 12.00 | 12.00 | 12.01 | 12.00 | 8.99 | 6.99 | 7.00 | 7.00 | 27.06 | 92.13 |
| Fixed Assets | 0.99 | 0.99 | 0.99 | 0.99 | 0.00 | 0.00 | 0.00 | 1.99 | 0.00 | 0.00 | 0.00 | 2.99 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.99 | 2.99 | 1.99 | 2.99 | 2.99 | 3.99 | 3.98 | 0.99 | 2.99 | 2.99 | 0.00 | 0.00 |
| Other Assets | 9.01 | 8.02 | 9.02 | 9.02 | 9.02 | 8.01 | 5.01 | 5.01 | 4.01 | 4.01 | 27.06 | 89.14 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.01 | 1.01 | 1.01 | 14.03 |
| Trade receivables | 0.00 | 0.00 | 0.00 | 0.99 | 1.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 17.93 | 58.74 |
| Cash & equivalents | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01 | 1.99 | 3.01 | 0.00 | 0.00 | 1.01 | 3.01 |
| Total Assets | 11.99 | 12.00 | 12.00 | 12.00 | 12.01 | 12.00 | 8.99 | 6.99 | 7.00 | 7.00 | 27.06 | 92.13 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | 0.00 | 2.01 | −1.01 | 1.01 | — | 1.01 | 1.01 | 1.01 | −2.01 | — | −14.03 | −22.06 |
| Cash from investing activity | 0.00 | −2.01 | 1.01 | −1.01 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 3.01 | −2.01 |
| Cash from financing activity | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 11.03 | 26.06 |
| Net cash flow | −1.01 | 0.00 | 0.00 | 0.00 | — | 1.01 | 1.01 | 1.01 | −2.01 | — | 1.01 | 2.01 |
| Capex | 0.11 | 0.15 | 0.17 | 0.24 | 0.07 | 0.02 | 0.31 | 1.87 | 0.00 | 0.00 | 0.12 | 3.27 |
| Free cash flow | −0.99 | 1.99 | −0.99 | 0.99 | — | 0.99 | 0.00 | −0.99 | −1.99 | — | −13.97 | −25.96 |
| CFO / OP % | −90.0% | 471.9% | −535.1% | 224.9% | — | 671.9% | −18.0% | −34.1% | — | — | −9,771.1% | −643.1% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 29 | 3 | 39 | 129 | 215 | 18 | 24 | 31 | 35 | 0 | 215 | 162 |
| Inventory days | 0 | — | 28 | 19 | 13 | 39 | 89 | 239 | 222 | 113 | 10 | 42 |
| Days payable | — | — | 0 | 55 | 14 | 6 | 5 | 0 | 15 | 0 | 116 | 117 |
| Cash conversion cycle | 30 | 4 | 68 | 95 | 216 | 54 | 111 | 271 | 244 | 114 | 111 | 88 |
| Working capital days | 2,226 | 2,585 | 864 | 933 | 859 | 1,712 | 820 | 648 | 744 | 347 | 198 | 123 |
| ROCE % | 1.0% | 1.0% | 1.0% | 3.0% | 1.0% | 1.0% | −30.9% | −19.0% | −1.0% | 0.0% | 1.0% | 10.1% |
For the Mar 2026 quarter, Novelix Pharmaceuticals reported sales of ₹25.18 Cr, up 20.6% year on year and net profit of ₹0.92 Cr, up 441.2% year on year. The operating margin was 5.1%.
Novelix Pharmaceuticals' sales for the year to Mar 2026 were ₹132 Cr; over the last twelve months they were ₹132 Cr.
Net profit for the year to Mar 2026 was ₹3.01 Cr, and ₹2.59 Cr over the last twelve months. Earnings per share over the same trailing period were ₹1.51.
Novelix Pharmaceuticals reported borrowings of ₹4.01 Cr at Mar 2026, against cash and equivalents of ₹3.01 Cr.
Cash from operations was −₹22.06 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹25.96 Cr.